ERBB2 and non-small cell lung carcinoma: In contrast to T-DM1, in the DESTINY-Lung01 study, T-DXd reached a median PFS of 8.2 months and a median OS of 17.8 months with acceptable toxic effects in previously treated patients with HER2-mutated NSCLC patients [218].